Introduction
v Ectopic ACTH syndrome (EAS) is an extremely rare cause of Cushing's syndrome in young children.
v The intensity of ACTH secretion and hypercortisolaemia is greater in EAS than in Cushing's disease.
v Control of hypercortisolaemia represents an important step in the management while awaiting localization of the ACTH source or in preparation to surgery.
v Etomidate was used as an anesthetic agent. It inhibits cortisol synthesis and its rapid onset of action makes it an ideal medication in severe hypercortisolaemia.
v We describe a case of Cushing syndrome in a child, due to an ectopic ACTH-secreting tumour managed with an etomidate infusion prior to surgical resection of the tumour.
Case Summary
v A 6-year-old girl presented with a 2-weeks history of headaches and vomiting on a background of excessive weight gain in the preceding 6 months.
v She had classic features of Cushing's syndrome (moon facies, plethoric cheeks, buffalo hump and striae) (Fig 1A and 1B) .
v Her weight was 45 kg (>99.6 th centile) and height 125.6 cm (91 st centile).
v She had severe hypertension (180/110 mmHg) and hypoxia with a fluctuating conscious level on admission (hypertensive encephalopathy).
v Investigations revealed markedly elevated serum cortisol (1445 nmol/L), elevated ACTH (99 ng/L) and 24 hour urinary free cortisol 4039nmol/day (0-260).
v MRI brain showed posterior reversible encephalopathy syndrome (PRES) and no pituitary adenoma.
v CT chest showed an enlarged partially calcified nodular thymus with localised lymphadenopathy, consistent with an ACTH secreting neuroendocrine tumour ( Figure 1C) . Histology of the resected tissue subsequently revealed a high grade neuroendocrine carcinoma.
v She had a diagnosis of hypertensive encephalopathy caused by Cushing's syndrome secondary to ectopic ACTH production from a thymic carcinoma ( Figure 1D ). 
Management
v Captopril was used for controlled reduction of blood pressure.
v Management involved cortisol secretion blockade using an intravenous etomidate infusion (Figure 2 ).
v Frequent serum cortisol monitoring was undertaken to achieve complete blockade and to prevent hypoadrenalism.
v Replacement with intravenous hydrocortisone (0.5-1 mg/h) and fludrocortisone was started when serum cortisol < 200 nmol/l.
v The target serum cortisol based on mean 24-h cortisol levels in patients in an intensive care setting was 500-800 nmol/l.
v Etomidate infusion was continued for 3 weeks while investigations were undertaken to localize the ACTH secreting tumour and until the patient was deemed stable to tolerate the surgery. No drowsiness or respiratory depression was observed.
v She underwent thymectomy however residual disease was found on CT a few weeks post-operatively explaining the rising cortisol levels ( Fig 1C) .
v Etomidate was recommenced at 3.5mg/h and subsequently a laparoscopic bilateral adrenalectomy was undertaken and the patient was commenced on replacement hydrocortisone and fludrocortisone prior to initiating chemotherapy.
